NasdaqGS:GILDBiotechs
Is New HIV Switch Data Reframing the Investment Case for Gilead Sciences’ Lenacapavir Platform (GILD)?
In February 2026, Gilead Sciences presented Phase 3 ARTISTRY-1 and ARTISTRY-2 data showing its investigational single-tablet bictegravir/lenacapavir HIV regimen maintained virologic suppression and was generally well tolerated, proving noninferior to both complex multi-tablet regimens and guideline-recommended single-tablet therapy through Week 48.
This potential new once-daily option could simplify treatment for people living with HIV who are currently on complex regimens, reinforcing...